Biogen Stock News

Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200. Over []

Lipe & Dalton lowered its position in Biogen Inc. (NASDAQ:BIIB) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,005 shares of the biotechnology company’s stock after selling 70 shares during the period. Biogen comprises approximately 1.5% of Lipe & Dalton’s holdings, making the stock […]

Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm in half starting Jan. 1 is “a day late and a dollar short,” according to Raymond James, which is not expecting the move to c

The moves follow a disappointing commercial launch of Aduhelm, as well as anger over the drugs high price.

In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to $28,000. In Q3, Biogen generated a mere

Biogen Inc. BIIB, +0.81% said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% starting Jan. 1 in an effort to get it to more patients with early signs of the disease. "For a pat

Related Stocks: ANTM , TGT , CL , MCK , GS , BIIB , MRNA , KSS , SBUX , ZBRA , IPG , MMM , PG , LLY , HON , ADSK , MRK , HLT , MO , BBY , ODFL , HUM , HPQ , LOW ,

TCI Wealth Advisors Inc. lessened its position in Biogen Inc. (NASDAQ:BIIB) by 26.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 814 shares of the biotechnology companys stock after selling 292 shares during the quarter. TCI Wealth Advisors Inc.s holdings in Biogen were []

Texas Permanent School Fund lowered its holdings in Biogen Inc. (NASDAQ:BIIB) by 7.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,024 shares of the biotechnology companys stock after selling 1,988 shares during the period. Texas Permanent School Funds []

Related Stocks: PYPL , EA , PLNT , UPS , CRM , BIIB , LYV , REGN , UNH , EOG , MA , FCX , MMM , BABA , MRK , FDX ,

Equities analysts forecast that Biogen Inc. (NASDAQ:BIIB) will announce sales of $2.63 billion for the current quarter, Zacks Investment Research reports. Twenty Nine analysts have issued estimates for Biogens earnings, with estimates ranging from $2.54 billion to $2.78 billion. Biogen posted sales of $2.85 billion during the same quarter last year, which would suggest a []

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

The European Medicines Agency has recommended the European Commission to reject Biogen Inc''s (NASDAQ: BIIB ) Aduhelm, an expected blow to its hopes of finding a widespread market for its struggling Alzheimer''s drug. The EMA recommendation had been expected since the EMA''s human medicines committee gave Biogen "a negative trend vote" after an oral presentation from the Company . Biogen said that it would Full story available on Benzinga.com

Biogen Alzheimer''s Drug Slapped With Negative EU Opinion Biogen Inc.''s controversial drug for Alzheimer''s disease was approved in the US over the summer. It was hailed as one of the most significant breakthrough treatments for degenerative brain diseases in years. But hopes to market the drug abroad, especially in Europe, have dimmed this morning after a European authority published a negative opinion on Aduhelm, according to Bloomberg . Aduhelm''s accelerated approval pathway in the US -- led to its approval in June. The drug works by reducing a protein called amyloid-beta from the brains of the patients for memory-robbing diseases. Biogen conducted two large clinical trials of the drug''s effect on Alzheimer''s patients with mild cognitive issues that produced conflicting results. There was discontent among folks in the medical community about the approval. Meanwhile, patient groups were enthusiastic that the first therapy to possibly slow the degenerative brain disease was available in nearly two decades.